Association of urinary uromodulin with kidney function decline and mortality: the health ABC study.

Permalink
https://escholarship.org/uc/item/0n57z9sg

Journal
Clinical nephrology, 87(6)

ISSN
0301-0430

Authors
Garimella, Pranav S
Katz, Ronit
Ix, Joachim H
et al.

Publication Date
2017-06-01

DOI
10.5414/cn109005

Peer reviewed
Association of urinary uromodulin with kidney function decline and mortality: the health ABC study

Pranav S. Garimella1, Ronit Katz2, Joachim H. Ix1, Linda F. Fried3, Stephen B. Kritchevsky4, Prasad Devarajan5, Michael R. Bennett5, Chirag R. Parikh6, Michael G. Shlipak7, Tamara B. Harris8, Orlando M. Gutiérrez9, and Mark J. Sarnak10, for the Health ABC Study

1University of California San Diego, San Diego, CA, 2University of Washington, Seattle, WA, 3VA Pittsburgh Healthcare System and University of Pittsburgh, Pittsburgh, PA, 4Wake Forest School of Medicine, Winston-Salem, NC, 5University of Cincinnati, Cincinnati, OH, 6Yale University School of Medicine, New Haven, CT, 7University of California, San Francisco, CA, 8National Institute on Aging, Bethesda, MD, 9University of Alabama at Birmingham, AL, and 10Tufts Medical Center, Boston, MA, USA

Abstract. Background: Urine uromodulin (uUMOD) is a protein secreted by the kidney tubule. Recent studies have suggested that higher uUMOD may be associated with improved kidney and mortality outcomes. Methods: Using a case-cohort design, we evaluated the association between baseline uUMOD levels and ≥ 30% estimated glomerular filtration rate (eGFR) decline, incident chronic kidney disease (CKD), rapid kidney function decline, and mortality using standard and modified Cox proportional hazards regression. Results: The median value of uUMOD was 25.8 µg/mL, mean age of participants was 74 years, 48% were women, and 39% were black. Persons with higher uUMOD had lower prevalence of diabetes and coronary artery disease (CAD), and had lower systolic blood pressure. Persons with higher uUMOD also had higher eGFR, lower urinary albumin to creatinine ratio (ACR), and lower C-reactive protein (CRP). There was no association of uUMOD with > 30% eGFR decline. In comparison to those in the lowest quartile of uUMOD, those in the highest quartile had a significantly (53%) lower risk of incident CKD (CI 73%, 18%) and a 51% lower risk of rapid kidney function decline (CI 76%, 1%) after multivariable adjustment. Higher uUMOD was associated with lower risk of mortality in demographic adjusted models, but not after multivariable adjustment. Conclusion: Higher levels of uUMOD are associated with lower risk of incident CKD and rapid kidney function decline. Additional studies are needed in the general population and in persons with advanced CKD to confirm these findings.

Introduction

The current assessment of kidney health and the definition of chronic kidney disease (CKD) are limited to measures or estimates of glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (ACR). Tubular health is essential for maintenance of acid-base status, mineral metabolism, and hormone production [1, 2]. In addition, tubular secretion is also the means by which medications are excreted through the kidneys. The kidney tubules may also have a role in preventing urinary infections. However, there are no biomarkers that have become accepted in clinical medicine as validated measures of tubular health.

Urinary uromodulin (uUMOD), also known as Tamm-Horsfall protein, is a 95-kDa glycoprotein synthesized by the thick ascending limb of the loop of Henle and early distal convoluted tubule. It is the most abundant urinary protein among healthy adults (20 – 70 mg/day) [3]. Mutations in the UMOD gene are associated with low uUMOD levels and cause congenital hyperuricemic, cystic kidney diseases, and kidney failure [4, 5]. In large genome-wide association studies (GWAS), the strongest associations with CKD were with common variants in the region of UMOD gene [6, 7]. As a result, there has been a renewed interest in the role of uUMOD in the development and progression of kidney disease.
Recently, our group has found that among participants enrolled in the Cardiovascular Health Study (CHS), each standard deviation (SD) higher uUMOD was associated with 23% lower odds of eGFR decline in models adjusted for demographics, eGFR, ACR, and CKD risk factors [8]. In addition, each SD higher uUMOD was also associated with 10% lower risk of mortality in adjusted models.

In the Health, Aging & Body Composition study (Health ABC), we aimed to validate our previous work and evaluate the association between uUMOD levels, kidney function decline and incident CKD from within the subcohort. KF = kidney function.

Methods

Participants

The Health ABC is a longitudinal study of the impact of changes in weight and body composition on age-related physiologic and functional changes. Community-dwelling adults (n = 3,075) aged 70 – 79 years were recruited from Medicare eligibility lists from March 1997 through July 1998 at two field centers in Pittsburgh, PA, and Memphis, TN. White participants were recruited from a random sample of the lists; black participants were recruited from all age-eligible individuals residing in the respective communities. Subjects were eligible if they reported no difficulty walking one-fourth of a mile, climbing up 10 steps, or performing basic activities of daily living; were free of life-threatening illness; planned to remain in the geographic area for ≥ 3 years; and were not enrolled in lifestyle intervention trials. Exclusion criteria included difficulties with activities of daily living, cognitive impairment, inability to communicate with the interviewer, intention of moving within the next 3 years, and active treatment for cancer in the preceding 3 years. All participants gave informed consent, and the study was approved by the institutional review boards at the University of Tennessee Health Science Center and the University of Pittsburgh.

Study design

We used a case-cohort design for this study, and Figure 1 depicts the sampling design for this study strategy. From the entire cohort of Health ABC (n = 3,075), we selected a random subcohort of 502 participants at year 1. Our primary outcomes were ≥ 30% eGFR decline and mortality. In addition to the random subcohort, cases were selected for ≥ 30% eGFR decline to ensure sufficient number of events and adequate statistical power. We defined decline as ≥ 30% decline in eGFR from the year-1 visit to the year-10 visit. If year 10 was missing, we used eGFR from the year-3 visit. Overall, there were 420 participants who had ≥ 30% decline in eGFR during the study period. Of these, 81 were already in the random subcohort, and an additional 339 participants with > 30% eGFR decline were identified from the entire Health ABC study population. As secondary outcomes, we also assessed for incident CKD (eGFR < 60 mL/min/1.73m² and at least 1 mL/min/1.73m²/year decline in eGFR in individuals with eGFR ≥ 60 mL/
Garimella, Katz, Ix, et al. 280

min/1.73m² at baseline) and rapid kidney function decline (> 3 mL/min/year decline in eGFR) in the subcohort only. As there were sufficient mortality events (n = 248) from within the random subcohort, we did not additionally sample for mortality. In aggregate, the random subcohort and the CKD progression cases provided an analysis cohort of 841 participants.

**Exposure variable**

Spot urine specimens were obtained at the time of the year-1 study visit and stored at −70 °C until thaw and uUMOD was measured at the University of Cincinnati Children’s Hospital Medical Center in 2015. Uromodulin was assayed in the urine using a commercially-available ELISA kit (MD Bioproducts, St. Paul, MN, USA) according to the manufacturer’s instructions. The assay is based on a colorimetric sandwich immunoassay utilizing a polyclonal antibody against human uromodulin as the capture antibody and a biotinylated polyclonal antibody against human uromodulin as the detection antibody. The correlation coefficient for this particular assay run was 1.00. The interassay coefficient of variation obtained by analyzing results from 81 duplicate measures spread between 10 separate assay runs was as 5.02%. The minimum detectable concentration as reported by the manufacturer was 0.75 ng/mL. No measured values in our cohort were below the detectable limit.

**Outcomes**

The eGFR was estimated using an equation that included serum cystatin C concentration, age, sex, and race derived in the CKD-EPI study [9]. A 30% decline in eGFR has recently been associated with adverse outcomes and therefore recommended as an alternative endpoint for CKD progression [10]. In secondary analysis, we used incident CKD (eGFR < 60 at year 3 or 10 and at least 1 mL/min decline in eGFR) and rapid kidney function decline defined by > 3 mL/min/year decline in eGFR, given their association with adverse clinical outcomes in prior studies [11]. Cystatin C was measured using a BNII nephelometer (Dade Behring Inc., Deerfield, IL, USA) that used a particle-enhanced immunonephelometric assay (N Latex Cystatin C) [12]. We used cystatin C-based eGFR estimates as creatinine was not isotope dilution mass spectrometry (IDMS) standardized at all the visits during follow-up thus increasing the risk of bias due to measurement variability.

The Health ABC Study Diagnosis and Disease Ascertainment Committee reviewed all hospital records, death certificates, informant interviews, and autopsy data to adjudicate immediate and underlying causes of death.

**Covariates**

Covariates for the models were selected a priori based on biological plausibility and prior published data regarding potential confounders of the associations of uUMOD with the clinical endpoints [8]. A series of sequential models were fit to evaluate the effects of adding certain sets of covariates. Traditional cardio-vascular disease (CVD) and kidney disease risk factors including age, gender, race/ethnicity, body mass index (BMI), physical activity level, smoking defined by current versus former (> 100 lifetime cigarettes) or never, diabetes (defined by use of hypoglycemic agents, fasting plasma glucose ≥ 126 mg/dL or nonfasting glucose ≥ 200 mg/dL), systolic blood pressure, low-density lipoprotein cholesterol level (LDL), high-density lipoprotein cholesterol level (HDL), statin medications, blood pressure medications including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, and C-reactive protein (CRP) were considered as confounding variables. Analyses were also adjusted for baseline eGFR and ACR.

**Statistical analysis**

We described the distribution of uUMOD using summary statistics and frequency histograms and compared baseline participant characteristics (demographics, kidney function, CVD risk factors) by uUMOD quartiles among members of the subcohort. We evalu-
ated the correlations of uUMOD, eGFR, and albuminuria using Spearman correlation coefficients. We evaluated each uUMOD-outcome association for the presence of nonlinearity using generalized additive models and restricted cubic splines. Risk estimates were calculated by categories of uUMOD (defined by quartiles of the distribution among the random subcohort) for all outcomes.

We evaluated the association of uUMOD with eGFR decline, using modified Cox regression to account for the case-cohort approach [13, 14]. Subcohort participants were weighted with the inverse of the sampling fraction. Cases that arose outside the subcohort were not weighted before their failure. All cases (irrespective of whether they arose in the subcohort or not) were assigned a weight of 1 at the time of failure. For each outcome, we fit a series of sequential models. Initial models were adjusted for age, sex, race, and clinic site. A subsequent model additionally adjusted for baseline eGFR and urine ACR. A final model included CVD and CKD risk factors (body mass index, diabetes, systolic blood pressure, blood pressure medication use, total cholesterol, lipid-lowering medication, CRP, and smoking status). We evaluated associations of uUMOD with mortality using a standard Cox proportional hazards regression. For the secondary analysis of kidney outcomes (incident CKD and rapid kidney function decline), we used standard Cox proportional hazards regression as these cases were restricted to the random subcohort, and no additional sampling was performed. The proportional hazards assumption was tested based on an extended version of the Schoenfeld residuals weighted Cox models [15]. For each of the clinical outcomes,
we evaluated whether the uUMOD-outcome association was modified by CKD status (defined as eGFR < 60 mL/min/1.73m²).

Analyses were conducted using R version 3.2.2 (2015-08-14) (R Core Team, Vienna, Austria) and IBM SPSS Statistics for Windows, Version 23.0. (IBM Corp, Armonk, NY, USA) [16]. Estimates with two-sided p-values < 0.05 were considered statistically significant.

Results

Baseline characteristics

Among the 502 randomly-selected participants at baseline, the median (Q1, Q3) value of uUMOD was 25.8 µg/mL (15.8, 40.2), and the distribution was right skewed. The mean ± SD age of participants was 74 ± 3 years, 48% were women, and 39% were black. The mean ± SD eGFR was 73 ± 18 mL/min/1.73 m², and median (Q1, Q3) urine ACR was 5 (4, 20) mg/g. Table 1 shows baseline characteristics by quartiles of uUMOD in the random subcohort. Compared to participants with low uUMOD, persons with higher levels were less likely to have diabetes or history of coronary artery disease (CAD), and had lower systolic blood pressure (BP). Persons with higher uUMOD also had higher eGFR, lower urinary ACR, and lower CRP.

### Table 2. Association of uUMOD with kidney outcomes and mortality in older community-living adults.

| uUMOD quartiles | Linear model |
|-----------------|--------------|
|                 | Per SD increase = 27.1 µg/mL | p-value |
| ≥ 30 eGFR decline (case-cohort design) | | |
| N               | 126          | 125          | 126          | 124          | 501          |
| Events          | 26           | 10           | 23           | 22           | 81           |
| Incidence rate (%/yr)* | 3.22        | 1.2          | 2.38         | 2.49         | 2.32         |
| Model 1**       | 1.00 (ref)   | 0.74 (0.48, 1.13) | 0.64 (0.41, 0.99) | 0.90 (0.58, 1.40) | 1.02 (0.86, 1.20) | 0.864 |
| Model 2†        | 1.00 (ref)   | 0.80 (0.52, 1.23) | 0.78 (0.50, 1.21) | 0.94 (0.60, 1.49) | 1.03 (0.86, 1.23) | 0.792 |
| Model 3‡        | 1.00 (ref)   | 0.82 (0.53, 1.26) | 0.93 (0.60, 1.44) | 1.10 (0.69, 1.75) | 1.08 (0.90, 1.29) | 0.418 |
| Incident CKD (subcohort only) | | |
| N               | 126          | 125          | 126          | 124          | 501          |
| Events          | 46           | 31           | 33           | 22           | 132          |
| Incidence rate (%/yr) | 5.70        | 3.72         | 3.41         | 2.49         | 3.78         |
| Model 1**       | 1.00 (ref)   | 0.62 (0.39, 0.99) | 0.50 (0.31, 0.80) | 0.40 (0.23, 0.69) | 0.75 (0.58, 0.97) | 0.029 |
| Model 2†        | 1.00 (ref)   | 0.69 (0.43, 1.11) | 0.59 (0.36, 0.97) | 0.44 (0.25, 0.76) | 0.77 (0.61, 0.99) | 0.037 |
| Model 3‡        | 1.00 (ref)   | 0.68 (0.41, 1.11) | 0.63 (0.38, 1.05) | 0.47 (0.27, 0.82) | 0.79 (0.52, 1.01) | 0.055 |
| Rapid kidney function decline (subcohort only) | | |
| N               | 88           | 103          | 104          | 94           | 389          |
| Events          | 28           | 15           | 32           | 16           | 91           |
| Incidence rate (%/yr) | 4.79        | 2.17         | 3.91         | 2.40         | 3.3          |
| Model 1**       | 1.00 (ref)   | 0.35 (0.17, 0.69) | 0.67 (0.39, 1.16) | 0.43 (0.22, 0.83) | 0.73 (0.52, 1.02) | 0.064 |
| Model 2†        | 1.00 (ref)   | 0.37 (0.18, 0.75) | 0.66 (0.38, 1.16) | 0.50 (0.25, 0.98) | 0.77 (0.55, 1.07) | 0.123 |
| Model 3‡        | 1.00 (ref)   | 0.35 (0.16, 0.73) | 0.60 (0.33, 1.10) | 0.49 (0.24, 0.99) | 0.76 (0.55, 1.06) | 0.109 |
| All-cause mortality (subcohort only) | | |
| N               | 126          | 125          | 126          | 125          | 502          |
| Events          | 68           | 68           | 55           | 57           | 248          |
| Incidence rate (%/yr) | 5.40        | 5.23         | 3.85         | 4.28         | 4.66         |
| Model 1**       | 1.00 (ref)   | 0.87 (0.61, 1.24) | 0.57 (0.39, 0.83) | 0.63 (0.43, 0.92) | 0.81 (0.68, 0.96) | 0.017 |
| Model 2†        | 1.00 (ref)   | 0.95 (0.67, 1.36) | 0.65 (0.44, 0.94) | 0.70 (0.48, 1.02) | 0.84 (0.71, 0.99) | 0.040 |
| Model 3‡        | 1.00 (ref)   | 1.09 (0.75, 1.59) | 0.74 (0.50, 1.10) | 0.79 (0.53, 1.17) | 0.86 (0.73, 1.02) | 0.084 |

*Incidence rate for > 30 eGFR decline is calculated from the random subcohort only. **Adjusted for age, gender, race, education, and site. †Additionally adjusted for estimated glomerular filtration rate and urine albumin-creatinine ratio. ‡Additionally adjusted for diabetes, systolic blood pressure, antihypertensive medications, smoking status, body mass index, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, statin use, and C-reactive protein.
**uUMOD and kidney outcomes**

There were 420 participants with ≥ 30% decline of eGFR during the follow-up period. There was no association of uUMOD when analyzed as a continuous variable (per SD increase) or as quartiles with ≥ 30% eGFR decline (Table 2). In secondary analyses restricted to only the random subcohort, there were 91 incident CKD events and 132 participants who experienced rapid kidney function decline. Compared to the participants in the first quartile, participants in the fourth quartile of uUMOD had > 50% lower hazard of incident CKD (HR 0.47 (0.27, 0.82)), after adjusting for confounders. Similarly, persons in the highest quartile of uUMOD also had a statistically significant lower hazard of rapid kidney function decline compared to persons in the lowest quartile of uUMOD (HR 0.49 (0.24, 0.99)).

**uUMOD and mortality**

There were 248 deaths within the subcohort over the duration of follow-up. After adjusting for age and demographics, each 1-SD higher uUMOD was associated with a 16% lower risk of death. This association lost statistical significance after adjusting for additional comorbidities and eGFR. After multivariable adjustment, the highest quartile of uUMOD was not associated with a statistically-significant risk of death in comparison with the lowest quartile (HR 0.79, (0.53, 1.17)) (Table 2).

We found no evidence of interaction between eGFR < 60 and uUMOD with the outcomes of ≥ 30% eGFR decline (p = 0.33), incident CKD (p = 0.14) or rapid kidney function decline (p = 0.80), and mortality (0.98).

**Discussion**

In summary, for two of our three kidney outcomes, and for mortality, we noted that higher levels of uUMOD were associated with a lower risk, although the results were not statistically significant in all models. These findings are consistent, in direction and magnitude, with prior data in older adults wherein we demonstrated that persons in the highest quartile of uUMOD had a lower risk of ≥ 30% eGFR decline and mortality [8].

The mechanisms linking uUMOD to kidney function decline may involve the prevention of urinary infections [17], stone formation [18] and its anti-inflammatory effects after tubular injury [19], although a clear causal role has yet to be established. As uUMOD is produced by kidney tubule cells, it is also possible that higher levels of uUMOD indicate better tubular function, such as erythropoietin production, maintenance of acid-base and mineral metabolism homeostasis.

Prior studies evaluating the association of uUMOD with kidney disease have shown conflicting results [6, 8, 20, 21]. These may in part be explained by select patient populations, small sample sizes, severity of underlying kidney disease, and differences in uUMOD assays. It has also been hypothesized that during renal injury, uUMOD may be upregulated and contribute to the repair of the kidney, whereas persistent injury and inflammation may result in fixed or lower levels of uUMOD [22], thus resulting in a bimodal association as has been demonstrated previously [23]. It has been postulated that polymorphisms in the UMOD gene seen in GWAS studies [6, 24] may lead to a phenotype with increased uUMOD expression, decreased membrane-anchoring efficiency, and faster protein trafficking or increased proteolytic release, which is associated with an increased risk of adverse clinical events [25].

Recently, two studies evaluated the clinical correlates of uUMOD in large population cohorts. The first study included two cohorts; the Swiss Kidney Project on Genes in Hypertension study in which 817 participants with kidney ultrasound measures provided 24-hour urine collections, and the Cohorte Lauzanoise study cohort in which 5706 adults provided morning spot urine samples [26]. In the second study, data from 943 participants in the CARTaGENE study were analyzed to study the determinants of uromodulin excretion in the general population aged 40 – 69 years [27]. Both studies reported significant positive correlation between uUMOD levels and eGFR after adjusting for multiple founders. In addition, a positive correlation was found between higher uUMOD excretion and urinary sodium, chloride, and uric
acid excretion, suggesting a potential role in salt and water homeostasis. Further, a positive linear correlation between uUMOD and kidney length and volume led the investigators to hypothesize that uUMOD may be a surrogate for kidney tubular function and reserve [26]. Additionally, two more recent studies in humans have shown that higher uUMOD levels are associated with a significantly lower risk of urinary tract infection (UTI) in community-dwelling older adults [17] and with lower risk of AKI in persons undergoing cardiac surgery [28]. Our study adds to this growing body of literature suggesting that higher uUMOD levels may be associated with better kidney function and clinical outcomes.

Our study is limited by a number of factors that should be considered. First, participants in the Health ABC cohort, although elderly, had relatively well-preserved kidney function. It is therefore unknown whether uUMOD would be differentially associated with outcomes in those with proteinuria and more advanced kidney disease. Although we found no evidence for an interaction with CKD, the small sample size limits the statistical power. Second, we used a single measure of kidney function at follow-up to determine eGFR decline, incident CKD, and rapid kidney function decline, which should ideally have been confirmed by a second value. Third, the findings of higher uUMOD being associated with less kidney function loss was limited to our secondary outcomes of incident CKD and rapid kidney function decline, and therefore need to be interpreted cautiously. Fourth, the samples in our study had been stored for nearly 15 years prior to analysis. Although storage even at −80 °C for 8 months can decrease levels of uUMOD [29], we believe this should be nondifferential with respect to the clinical outcomes. Our study also has a number of strengths.
The Health ABC cohort has detailed ascertainment of risk factors, covariates, and outcomes as well as the ability to adjust for measures of kidney function. We used a laboratory that has extensive experience with these measures including using the same assay as has been done in prior studies [8, 28].

In summary, results from our study are consistent with prior data indicating that higher levels of uUMOD may imply “healthier tubules” and better prognosis from the kidney and mortality standpoint. These findings improve our understanding of the different facets of kidney health and function above and beyond the traditional measures of eGFR and ACR. Studies are needed in more generalizable populations and those with more advanced stages of CKD to evaluate whether higher levels of uUMOD are similarly associated with better kidney and mortality outcomes.

**Funding**

This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH) and the National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050, and NINR grant R01-NR012459. Drs Shlipak, Sarnak, Jr, and Katz were supported by NIA grant 5R01AG027002, and Dr. Ix by an American Heart Association Award #14EIA18560026 and NIDDK:K24DK110427. Dr. Devarajan was supported by National Institutes of Health (NIH) grant R01 DK096418. The study sponsors had no role in study design; collection, analysis, and interpretation of the data; writing the report; and the decision to submit the report for publication.

**References**

[1] Briet M, Bozec E, Laurent S, Fassot C, London GM, Jacquot C, Froissart M, Houllier P, Boutouyrie P. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int. 2006; 69: 350-357. PubMed CrossRef

[2] Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, Levey AS, Sarnak MJ. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005; 16: 3403-3410. PubMed CrossRef

[3] Lhotta K. Uromodulin and chronic kidney disease. Kidney Blood Press Res. 2010; 33: 393-398. PubMed CrossRef

[4] Dahan K, Devaux O, Smoors M, Vertommen D, Louste G, Poux JM, Viron B, Jacquot C, Gagnadoux MF, Chauveau D, Bichler M, Cochot P, Coysyn JP, Mougenot B, Rider MH, Antignac C, Verellen-Dumoulin C, Pirson Y. A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol. 2003; 14: 2883-2893. PubMed CrossRef

[5] Hart TC, Gorry MC, Hart PS, Woodward AS, Shihabhi Z, Sandhu J, Shirts B, Xu L, Zhu H, Barmada MM, Bleyer AJ. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet. 2002; 39: 882-892. PubMed CrossRef

[6] Köttgen A, Hwang SJ, Larson MG, Van Eyk JE, Fu Q, Benjamin EJ, Dehghan A, Glazer NL, Kao WH, Harris TB, Gudnason V, Shlipak MG, Yang Q, Coresh J, Levy D, Fox CS. Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol. 2010; 21: 337-344. PubMed CrossRef

[7] Köttgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, Yang Q, Gudnason V, Launer LJ, Harris TB, Smith AV, Arking DE, Astor BC, Boerwinkle E, Ehret GB, Ruczinski I, Scharpf RB, Chen YD, de Boer IH, Haritunians T, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet. 2009; 41: 712-717. PubMed CrossRef

[8] Garimella PS, Biggs ML, Katz R, Ix JH, Bennett MR, Devarajan P, Kestenbaum BR, Siscovick DS, Jensen MK, Shlipak MG, Chaves PH, Sarnak MJ. Urinary uromodulin, kidney function, and cardiovascular disease in elderly adults. Kidney Int. 2015; 88: 1126-1134. PubMed CrossRef

[9] Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kasek J, Rossert J, Van Lente F, Bruce RD III, Zhang YL, Greene T, Levey AS. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008; 51: 395-406. PubMed CrossRef

[10] Coresh J, Turin TC, Matsushita K, Sang Y, Ballev SH, Appel LJ, Arima H, Chadban SJ, Cicillii M, Djurdjevic O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ozbaba T, Shalev V, et al;CKD Prognosis Consortium. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014; 311: 2518-2531. PubMed CrossRef

[11] Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, Newman AB, Sarnak MJ. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med. 2008; 168: 2212-2218. PubMed CrossRef

[12] Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005; 352: 2049-2060. PubMed CrossRef
[13] Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999; 52: 1165-1172. PubMed CrossRef
[14] Therneau TM, Li H. Computing the Cox model for case cohort designs. Lifetime Data Anal. 1999; 5: 99-112. PubMed CrossRef
[15] Xue X, Xie X, Gunter M, Rohan TE. Wasserheit-Smollner S, Ho GY, Civillo D, Yu H, Strickler HD. Testing the proportional hazards assumption in case-cohort analysis. BMC Med Res Methodol. 2013; 13: 88. PubMed CrossRef
[16] R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria; 2013. http://www.R-project.org./
[17] Garimella PS, Bartz TM, Is JH, Chonchol M, Shlipak MG, Devarajan P, Bennett MR, Sarnak MJ. Urinary uromodulin and risk for urinary tract infection: The Cardiovascular Health Study. Am J Kidney Dis. 2016. In Press. CrossRef
[18] Liu Y, Mo L, Goldfarb DS, Evan AP, Liang F, Khan SR, Lieske JC, Wu XR. Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein. Am J Physiol Renal Physiol. 2010; 299: F469-F478. PubMed CrossRef
[19] El-Achkar TM, Wu XR, Rauhman M, McCracken R, Kiefer S, Dagher PC. Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression. Am J Physiol Renal Physiol. 2008; 295: F534-F544. PubMed CrossRef
[20] Pruijm M, Ponte B, Ackermann D, Paccaud F, Guessous I, Ehret G, Pechère-Bertschi A, Vogt B, Mohaupt MG, Martin PY, Youhanna SC, Nägele N, Vollenweider P, Waeger B, Burnier M, Devuyst O. Bochud M. Associations of Urinary Uromodulin with Clinical Characteristics and Markers of Tubular Function in the General Population. Clin J Am Soc Nephrol. 2016; 11: 70-80. PubMed CrossRef
[21] Zhou J, Chen Y, Liu Y, Shi S, Wang S, Li X, Zhang H, Wang H. Urinary uromodulin excretion predicts progression of chronic kidney disease resulting from IgA nephropathy. PLoS One. 2013; 8: e71023. PubMed CrossRef
[22] El-Achkar TM, Wu XR. Uromodulin in kidney injury: an instigator, bystander, or protector? Am J Kidney Dis. 2012; 59: 452-461. PubMed CrossRef
[23] Reznichenko A, van Dijk MC, van der Heide JH, Bakker SJ, Seelen M, Navis G. Uromodulin in renal transplant recipients: elevated urinary levels and bimodal association with graft failure. Am J Nephrol. 2011; 34: 445-451. PubMed CrossRef
[24] Olden M, Corre T, Hayward C, Toniolo D, Ulivi S, Gasparini P, Pistis G, Hwang SJ, Bergmann S, Campbell H, Cossa M, Gandin I, Girotto G, Glaudemans B, Hastie ND, Lofting J, Polasek O, Rampoldi L, Rudan I, Sala C, et al. Common variants in UMOD associate with urinary uromodulin levels: a meta-analysis. J Am Soc Nephrol. 2014; 25: 1869-1882. PubMed CrossRef
[25] Rampoldi L, Scolari F, Amoroso A, Ghigrieri G, Devuyst O. The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int. 2011; 80: 338-347. PubMed CrossRef
[26] Pruijm M, Ponte B, Ackermann D, Paccaud F, Guessous I, Ehret G, Pechère-Bertschi A, Vogt B, Mohaupt MG, Martin PY, Youhanna SC, Nägele N, Vollenweider P, Waeger B, Burnier M, Devuyst O, Bochud M. Associations of Urinary Uromodulin with Clinical Characteristics and Markers of Tubular Function in the General Population. Clin J Am Soc Nephrol. 2016; 11: 70-80. PubMed CrossRef
[27] Troyanov S, Delmas-Frenette C, Bollée G, Youhanna S, Brust V, Avadaila P, Devuyst O, Madore F. Clinical, genetic, and urinary factors associated with uromodulin excretion. Clin J Am Soc Nephrol. 2016; 11: 62-69. PubMed CrossRef
[28] Garimella PS, Jaber BL, Tigkiaouart H, Liangos O, Bennett MR, Devarajan P, El-Achkar TM, Sarnak MJ. Preoperative urinary uromodulin and acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol. 2017; 12: 10-18. PubMed CrossRef
[29] Youhanna S, Weber J, Beauneau V, Glaudemans B, Sobek J, Devuyst O. Determination of uromodulin in human urine: influence of storage and processing. Nephrol Dial Transplant. 2014; 29: 136-145. PubMed CrossRef